INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Geron Corporation - GERN

1. Pomerantz LLP is investigating claims against Geron Corporation for securities fraud. 2. Geron reported flat revenue trends for Rytelo in Q4 2024 earnings call. 3. Stock price fell sharply following the announcement on February 26, 2025. 4. Investors are encouraged to join the class action investigation against Geron. 5. Pomerantz, a top litigation firm, specializes in securities fraud cases.

Legal

75

3m saved

Insight

Article

FAQ

Why Very Bearish?

The investigation of securities fraud alongside flat revenue signals serious investor concerns, leading to a significant stock price drop, historically seen in similar cases where companies faced legal scrutiny, like with Valeant Pharmaceuticals in 2015.

How important is it?

The news indicates potential severe legal implications for Geron, affecting investor confidence and stock prices, which directly correlates with GERN’s market performance.

Why Short Term?

The immediate impact from the investigation and poor revenue performance will likely influence stock prices in the near future. Historical trends show that such news usually has rapid effects on market perception.

Related Companies

VLRX AXSM BIOC

NEW YORK, Feb. 26, 2025 /PRNewswire/ --

Pomerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Geron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Click here for information about joining the class action

On February 26, 2025, Geron announced its financial results for the fourth quarter and full year 2024. During a related earnings call, Geron's executives said that the Company has "observed flat revenue trends over the last few months" for its recently approved blood-disorder drug, Rytelo.

On this news, Geron's stock price fell sharply during intraday trading on February 26, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP